The Reform Path: A Meridian Model Bill for Cannabis Regulation in Mauritius
The argument against cannabis regulation in Mauritius has, over forty-four articles, been exhaustively examined and found to rest on no pharmacological, constitutional, economic, or comparative policy foundation that survives scrutiny. The argument is not the obstacle. The obstacle is institutional inertia in the absence of a drafted alternative. The Meridian Intelligence Desk removes that obstacle. This article presents six legislative and administrative instruments, each drafted in precise regulatory language, each grounded in the enacted law of a functioning cannabis regulatory jurisdiction, and each calibrated to the specific constitutional, fiscal, and public health context of the Republic of Mauritius. These instruments, taken together, constitute a complete regulatory framework. They require no new constitutional amendment. They require no international treaty renegotiation. They require one ministerial decision and the political will to implement what Parliament already voted for in 2022.
The task of this article is legislative, not rhetorical. The case for cannabis regulation in Mauritius has been made in this publication across eight chapters, forty-four articles, and the combined pharmacological, historical, constitutional, economic, and comparative policy record of the global cannabis reform movement. That case does not require restatement here. What requires drafting is the mechanism through which the policy changes. The Meridian Intelligence Desk presents that mechanism in six instruments, each precise enough to serve as a drafting instruction to the Mauritius Attorney General's Office, the Ministry of Health, and the Mauritius Revenue Authority, and each constructed to withstand challenge before the Supreme Court of Mauritius, the Privy Council, and any international treaty body that might examine it.
Mauritius cannabis model bill reform path six instruments 2022 amendment proclamation licensing authority pharmacovigilance age verification excise tax expungement Canada Germany Lesotho South Africa precedent
Mauritius is a signatory to the 1961 UN Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. No instrument in this model bill requires Mauritius to breach any of those treaty obligations. Article 2(5)(b) of the 1961 Single Convention explicitly permits parties to apply to cannabis the same controls as to other narcotic drugs while establishing a medical and scientific use framework. Article 4(c) requires parties to limit exclusively to medical and scientific purposes the production, manufacture, export, import, distribution of, trade in, use and possession of drugs. A regulated medical cannabis framework operates within the Article 4(c) framework, not outside it. Germany, Canada, the Netherlands, Malta, Luxembourg, and South Africa are all signatories to the 1961 Convention and have each established regulated cannabis frameworks without treaty breach. The international treaty objection to the model bill is not legally sustainable and has not been sustained in any of those jurisdictions.
This proclamation shall be published in the Government Gazette and shall come into immediate force upon publication.
Signed: Minister of Health, Republic of Mauritius.
The 2022 amendment is fully enacted law. It requires no further parliamentary action. The Minister of Health holds the proclamation power under the amendment's own commencement provisions. The instrument can be signed, gazetted, and in force within 24 hours of a ministerial decision. There is no legal impediment of any kind. The impediment is exclusively political.
The proclamation should specify a 90-day constitution period for the Mauritius Medical Cannabis Regulatory Authority (MMCRA), to be established under Instrument II below. The proclamation should simultaneously suspend, by ministerial direction to the DPP, the prosecution of cases involving personal cannabis possession pending the full implementation of the regulatory framework, mirroring the approach taken by the South African DPP following the 2018 Constitutional Court ruling.
Functions. The Authority shall (a) issue, renew, suspend, and revoke licences for the cultivation, processing, testing, distribution, and dispensing of medical cannabis and cannabis-derived products; (b) establish and maintain a register of all licensed operators; (c) set and enforce quality standards for licensed medical cannabis products; (d) advise the Minister on regulatory amendments required to ensure the continued effectiveness of the framework; and (e) publish annual reports on the operation of the licensed market including retail price data, licence holder compliance records, and market displacement of illegal supply.
Licensing Classes. The Authority shall issue licences in the following classes: Class A (Cultivation), Class B (Processing and Extraction), Class C (Testing Laboratory), Class D (Wholesale Distribution), Class E (Medical Dispensary), and Class F (Export). No person shall operate in any licensed class without a current licence. Licences shall be issued for a period of three years and are renewable upon application and satisfactory compliance review.
Disqualification. No licence shall be issued to any person convicted of a serious criminal offence within the preceding ten years, to any company whose beneficial ownership cannot be verified to the satisfaction of the Authority, or to any entity that has been the subject of a money laundering finding by a competent authority.
The MMCRA is modelled structurally on the Lesotho Cannabis Authority established under the Lesotho Medicines and Medical Devices Authority Act as amended in 2020, adapted to the Mauritian institutional context. The six-licence classification system mirrors the Canadian federal licensing structure under the Cannabis Act 2018, simplified for a small island market. The disqualification provisions follow the German CanG transparency requirements for Cannabis Social Club management.
The Authority should be housed within the Ministry of Health's existing regulatory infrastructure to minimise establishment costs. The Mauritius Pharmacy Board and the Food and Drug Authority provide institutional templates for the governance model. Licence fees, calibrated to reflect the scale of operation and the class of licence, should be set to cover the Authority's operating costs without creating a prohibitive barrier to entry for small-scale operators.
Qualifying Conditions. The Minister, acting on the advice of a Clinical Advisory Panel constituted by the Ministry of Health, shall publish by notice in the Government Gazette a schedule of qualifying medical conditions for which medical cannabis may be prescribed. The initial schedule shall include, at minimum: (a) chronic neuropathic pain refractory to standard analgesic treatment; (b) chemotherapy-induced nausea and vomiting refractory to standard antiemetic treatment; (c) multiple sclerosis-associated spasticity; (d) severe treatment-resistant epilepsy in patients under 18 years of age; and (e) palliative care for patients with a terminal diagnosis. The Clinical Advisory Panel may add further qualifying conditions upon the submission of peer-reviewed clinical evidence.
Adverse Event Reporting. Every licensed Class E dispensary shall report to the National Pharmacovigilance Centre any adverse event associated with the use of a medical cannabis product within 72 hours of the event being brought to its attention. The Authority shall compile and publish aggregate adverse event data annually. Any Class C Testing Laboratory that identifies a quality or contamination issue in a licensed product shall notify the Authority within 24 hours and shall retain the affected batch pending Authority investigation.
Product Standards. All medical cannabis products dispensed under a Class E licence shall (a) have been tested by a licensed Class C laboratory; (b) carry a certificate of analysis specifying THC content, CBD content, moisture level, microbiological safety, and absence of pesticide residue; and (c) be packaged in child-resistant containers bearing the batch number, test certificate reference, dispensary name, patient name, qualifying condition, prescribed dosage, and the statutory warning: MEDICAL CANNABIS PRODUCT. KEEP OUT OF REACH OF CHILDREN. NOT FOR RESALE.
The qualifying conditions schedule follows the structure of the UK Medical Cannabis Advisory Board's clinical framework under the 2018 licensing regime, with the addition of the paediatric epilepsy category drawn from the FDA's Epidiolex approval criteria. The adverse event reporting requirement mirrors the European Medicines Agency's pharmacovigilance framework under Directive 2001/83/EC.
The National Pharmacovigilance Centre already exists within the Ministry of Health's institutional infrastructure. No new institution is required. The Clinical Advisory Panel should include at minimum one neurologist, one oncologist, one pain management specialist, one pharmacist, and one public health physician. The panel's terms of reference and qualifying conditions schedule should be published within 60 days of the Authority's constitution.
Supply Chain Integrity. Every licensed operator shall maintain a complete digital record of every transaction in the licensed cannabis supply chain from cultivation through processing, testing, distribution, and dispensing. These records shall be maintained for a minimum of five years and shall be available for inspection by the Authority at any time without prior notice. The Authority shall establish a centralised tracking system, compatible with the seed-to-sale model operated under the Canadian Cannabis Act Regulations and the Colorado Marijuana Enforcement Division's METRC system, within 12 months of the proclamation date.
Prohibition of Unlicensed Sales. Any person who sells, offers for sale, or distributes cannabis or cannabis-derived products without a current licence issued by the Authority commits an offence and shall be liable on conviction on indictment to a fine not exceeding [amount] and to imprisonment for a term not exceeding [x] years. The penalties applicable to unlicensed sales shall be calibrated to be significantly more severe than those applicable to personal possession, to concentrate prosecutorial and police resources on commercial unlicensed operators rather than individual consumers.
Advertising Prohibition. No licensed operator shall advertise medical cannabis products to the general public through any medium. Communications between licensed operators and registered patients shall be restricted to clinical information provided at the dispensary. No product shall be branded in a manner designed to appeal to persons under the age of 18.
The seed-to-sale tracking requirement is the single most important market integrity provision in the framework. It is the mechanism that most effectively prevents licensed product from leaking into the illegal market and illegal product from entering the licensed supply chain. Colorado's METRC system and Canada's federal cannabis tracking system provide directly replicable technical models. The MMCRA should contract a technology provider with experience in cannabis track-and-trace systems within 60 days of constitution.
The calibration of unlicensed sale penalties is deliberate and important. The existing DDA 2000 applies equivalent penalties to personal possession and commercial trafficking. That equivalence is unjust and counterproductive. The model bill separates the two categories clearly: personal possession of quantities consistent with personal use is handled through the framework's decriminalisation approach under Instrument VI. Commercial unlicensed sale carries the full weight of criminal sanction. This calibration concentrates enforcement resources where they produce the greatest public benefit.
VAT. Medical cannabis products dispensed pursuant to a valid prescription under the licensed framework shall be zero-rated for value added tax purposes, consistent with the zero-rating applied to other prescription medicines under Schedule 1 to the Value Added Tax Act 1998. This zero-rating reflects the medical character of the dispensed product and ensures that the cost to patients is not inflated by a consumption tax applicable to non-medical goods.
Recommended Retail Price Ceiling. The Authority, in consultation with the Ministry of Finance and the Mauritius Revenue Authority, shall establish a recommended retail price ceiling for each licensed product category. The ceiling shall be set at a level sufficient to (a) cover the full regulated production, processing, testing, and distribution cost; (b) generate the excise duty revenue specified above; and (c) be sufficiently competitive with the illegal market to generate meaningful demand displacement from unlicensed to licensed supply. In no case shall the recommended retail price ceiling exceed Rs 500 per gram for botanical medical cannabis product in the initial regulatory period.
Revenue Allocation. Excise revenue collected on medical cannabis products shall be allocated as follows: 40 per cent to the Ministry of Health for drug treatment and harm reduction programmes; 30 per cent to the National Agency for Drug Control for synthetic cannabinoid enforcement operations; 20 per cent to the MMCRA for its operating costs; and 10 per cent to a Cannabis Victim Compensation Fund established under Instrument VI.
The Rs 500 per gram retail price ceiling is the critical market design parameter. The illegal cannabis market in Mauritius is priced at Rs 1,200 to Rs 3,000 per gram. A regulated retail price at or below Rs 500 per gram eliminates the economic incentive for most consumers to purchase from illegal channels. The synthetic cannabinoid market, which sells at Rs 100 per dose, is driven by users who cannot afford natural cannabis at Rs 3,000 per gram. A regulated Rs 500 per gram alternative eliminates most of the economic displacement that created the synthetic market.
The 15% excise rate is drawn from Colorado's excise structure and is deliberately conservative relative to higher rates applied in some jurisdictions. A rate calibrated to market suppression, rather than maximum revenue extraction, produces better long-term fiscal outcomes by expanding the licensed market volume over time. The revenue allocation formula ensures that the regulated market directly funds the public health infrastructure that prohibition was supposed to protect.
Qualifying Convictions. Without limiting the generality of the foregoing, the following categories of conviction shall be prima facie qualifying for expungement: (a) possession of cannabis for personal use in a quantity not exceeding the personal use threshold established by the Authority; (b) cultivation of cannabis for personal use involving not more than [x] plants; and (c) any offence for which the original conviction was under section 34 (unlawful use) of the Dangerous Drugs Act 2000.
Procedure. An application for expungement shall be made by filing a Form [X] with the Registrar of the Supreme Court. The DPP shall have 30 days to file an objection to an application on the grounds that the conduct underlying the conviction would still constitute an offence under the regulated framework. In the absence of a DPP objection within 30 days, the expungement order shall be granted as of right. Where the DPP objects, the matter shall be listed before a single judge of the Supreme Court for determination.
Effect of Expungement. An expungement order shall have the effect of (a) removing the conviction from the person's criminal record maintained by the Mauritius Police Force; (b) restoring any civil service eligibility, professional licence, or other right suspended by reason of the expunged conviction; and (c) entitling the person to state in any application for employment, professional registration, or other purpose that they have no criminal conviction. No adverse inference shall be drawn from the existence of the expunged conviction in any civil, administrative, or professional proceeding.
Cannabis Victim Compensation Fund. There shall be established a Cannabis Victim Compensation Fund, administered by the Ministry of Justice, from which payments may be made to persons who demonstrate that they suffered material financial loss as a direct consequence of a conviction that has been expunged under this Act. The Fund shall be capitalised from 10 per cent of annual medical cannabis excise revenue as specified in Instrument V.
The expungement instrument is not merely a matter of justice, though it is that. It is a matter of constitutional coherence. The state cannot simultaneously acknowledge, through the 2022 amendment and the medical cannabis framework, that cannabis has legitimate uses, and maintain on the criminal records of its citizens the convictions it imposed for conduct it has now decided to permit. The expungement obligation follows logically from the regulatory decision. Canada implemented automatic expungement for simple possession offences under the Expungement of Historically Unjust Convictions Act 2018. Illinois implemented automatic expungement for prior cannabis convictions following recreational legalisation in 2019. South Africa's Cannabis for Private Purposes Act 2024 includes expungement provisions.
The compensation fund is a novel feature not present in all comparative jurisdictions but is appropriate in Mauritius given the documented evidence of wrongful provisional charges, career destruction, and professional harm caused by cannabis enforcement. The 10% excise allocation ensures the fund is self-sustaining from regulated market revenue rather than requiring general budget appropriation.
These six instruments do not require political courage of a kind that has not already been demonstrated. Parliament demonstrated it in 2022 when it passed the amendment. What they require is administrative decision-making of a kind that is exercised by ministers in this country every working day. The decision to sign a proclamation. The decision to constitute an authority. The decision to publish a schedule of qualifying conditions. These are not extraordinary acts. They are the ordinary business of government. The extraordinary act was done in 2022. It was called the Dangerous Drugs (Amendment) Act.
The six instruments set out in this article constitute a complete, treaty-compatible, constitutionally sound, and fiscally responsible medical cannabis regulatory framework for the Republic of Mauritius. Each instrument has been drawn from the enacted law of a functioning regulatory jurisdiction. Each has been tested in the courts or regulatory systems of the jurisdiction from which it is drawn. None requires Mauritius to break new legal ground. The ground has been broken, in Canada, in Germany, in South Africa, in Lesotho, in Colorado, in Illinois, in Malta, in Luxembourg, and in the Mauritian National Assembly itself on the day the 2022 amendment passed its third reading.
The argument that Mauritius lacks the institutional capacity to implement this framework is not available to a government that operates the Mauritius Revenue Authority, the Financial Services Commission, the Pharmacy Board, the Food and Drug Authority, and the National Pharmacovigilance Centre. The argument that the international treaty obligations prevent implementation has been answered by every G7 nation and by eight African jurisdictions that have implemented equivalent frameworks under the same treaty obligations.
What remains is a decision. The decision to sign Instrument I. Everything that follows is implementation. The Meridian Intelligence Desk has drafted the instruments. The legal basis is in the Government Gazette. The political will is the only thing that is not yet on paper.
This is the fourth article of Chapter Eight: The Reform, in The Colonised Plant: The Cannabis Edition, June 2026. The two closing essays follow. The complete edition is published at themeridian.info/june-2026.
Add comment
Comments